ID25640A - Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya - Google Patents

Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya

Info

Publication number
ID25640A
ID25640A IDW20001680A ID20001680A ID25640A ID 25640 A ID25640 A ID 25640A ID W20001680 A IDW20001680 A ID W20001680A ID 20001680 A ID20001680 A ID 20001680A ID 25640 A ID25640 A ID 25640A
Authority
ID
Indonesia
Prior art keywords
antagonistics
preparates
aii
production
continuous release
Prior art date
Application number
IDW20001680A
Other languages
English (en)
Indonesian (id)
Inventor
Yasutaka Igari
Akira Saikawa
Yoshiyuki Inada
Shigeru Kamei
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of ID25640A publication Critical patent/ID25640A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW20001680A 1998-03-04 1999-03-03 Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya ID25640A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5236698 1998-03-04

Publications (1)

Publication Number Publication Date
ID25640A true ID25640A (id) 2000-10-19

Family

ID=12912818

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001680A ID25640A (id) 1998-03-04 1999-03-03 Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya

Country Status (21)

Country Link
US (2) US6589547B1 (et)
EP (1) EP1058541B1 (et)
KR (1) KR20010086245A (et)
CN (1) CN1291888A (et)
AT (1) ATE258430T1 (et)
AU (1) AU2745199A (et)
BR (1) BR9908474A (et)
CA (1) CA2318446C (et)
DE (1) DE69914460T2 (et)
EE (1) EE200000499A (et)
ES (1) ES2214013T3 (et)
HU (1) HUP0101439A3 (et)
ID (1) ID25640A (et)
IL (1) IL137979A0 (et)
LT (1) LT4800B (et)
LV (1) LV12585B (et)
NO (1) NO20004350L (et)
PL (1) PL342684A1 (et)
SK (1) SK11902000A3 (et)
WO (1) WO1999044590A1 (et)
ZA (1) ZA991706B (et)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA991706B (en) * 1998-03-04 2000-10-03 Takeda Chemical Industries Ltd Sustained-release preparation for Aii Antagonist, production and use thereof.
BR0010084A (pt) 1999-04-28 2002-01-15 Takeda Chemical Industries Ltd Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
EP1262180A4 (en) * 2000-02-18 2005-06-01 Takeda Pharmaceutical TNF-ALPHA HEMMER
CA2400845A1 (en) * 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active compound slightly soluble in water and production process and use of the same
WO2002015935A1 (fr) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Agents de reduction du fibrinogene
CA2426674A1 (en) * 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Agent for preventing or treating portal hypertension
WO2002074340A1 (fr) * 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
BRPI0105509B8 (pt) * 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
EP1444988A4 (en) * 2001-11-13 2007-04-25 Takeda Pharmaceutical CANCER AGENT
EP1452176A4 (en) * 2001-12-03 2009-01-21 Takeda Pharmaceutical MEANS FOR IMPROVING INSULIN RESISTANCE
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
CN100438911C (zh) * 2002-12-27 2008-12-03 武田药品工业株式会社 体重增加抑制剂
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
ATE437884T1 (de) * 2003-05-29 2009-08-15 Jay W Pettegrew Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
AU2005249794A1 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
BRPI0516246A (pt) * 2004-10-07 2008-08-26 Takeda Pharmaceutical agente para a profilaxia ou tratamento de sìndrome metabólica, método para a profilaxia ou tratamento de sìndrome metabólica em um mamìfero, e, uso de ácido 2-etóxi-1-[ [2'-(5-oxo-2,5-diidro-1,2,4-oxadiazol-3-il) bifenil-4-il]metil] -1h-benzimidazol-7-carboxìlico ou um sal do mesmo ou uma pró-droga do mesmo em combinação com uma substáncia semelhante ao agonista de ppargama
EP1806137A4 (en) * 2004-10-29 2011-03-30 Kowa Co THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE
EP1850835A1 (fr) * 2005-02-21 2007-11-07 Flamel Technologies Forme pharmaceutique orale de losartan
JP4795362B2 (ja) * 2005-03-30 2011-10-19 武田薬品工業株式会社 ベンズイミダゾール誘導体およびその用途
JP2009504800A (ja) * 2005-08-22 2009-02-05 アレンビク リミテッド バルサルタンの調製方法
ZA200901075B (en) * 2006-08-10 2010-05-26 Takeda Pharmaceutical Pharmaceutical composition
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CL2007003658A1 (es) 2006-12-18 2008-05-09 Takeda Pharmaceutical Composicion de liberacion sostenida que comprende un peptido; procedimiento para preparar dicha composicion; agente profilactico o terapeutico para cancer de prostata, hiperplasia prostatica, endometriosis, fibroide uterino, fibroma uterino, pubertad
CN101011393B (zh) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 厄贝沙坦胃内滞留型缓释药物组合物
PE20130210A1 (es) * 2007-03-28 2013-03-11 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
WO2009134057A2 (ko) * 2008-04-29 2009-11-05 한올제약주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
ES2598490T3 (es) 2009-05-20 2017-01-27 Boehringer Ingelheim Vetmedica Gmbh Disolución farmacéutica bebible de telmisartán
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2751907A (en) * 1953-09-18 1956-06-26 Bishop & Co Platinum Works J Pellet injector
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
JPS58157768A (ja) 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4820843A (en) 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4898732A (en) * 1988-05-04 1990-02-06 The Clinipad Corporation Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
ATE107517T1 (de) * 1989-05-25 1994-07-15 Takeda Chemical Industries Ltd Transdermales therapeutisches mittel.
EP0403158A3 (en) 1989-06-14 1991-12-18 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
KR0163595B1 (ko) 1989-06-30 1998-12-01 미리암디, 메코너헤이 치환된 이미다졸
CA2020073A1 (en) 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
EP0411507B1 (en) 1989-08-02 1994-10-26 Takeda Chemical Industries, Ltd. Pyrazole derivatives, their production and use
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
EP0434038A1 (en) 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
EP0442473B1 (en) 1990-02-15 1998-08-19 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
CA2036618C (en) * 1990-02-22 2002-10-29 Akira Morimoto Fused thiophene derivatives, their production and use
IL99246A0 (en) * 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
TW274551B (et) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
WO1993004046A1 (en) * 1991-08-19 1993-03-04 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
TW284688B (et) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB2272899A (en) * 1992-11-30 1994-06-01 Du Pont Merck Pharma Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles
ATE204276T1 (de) 1992-12-22 2001-09-15 Takeda Chemical Industries Ltd Heterocyclische verbindungen mit angiotensin-ii- antagonistischer wirkung und ihre anwendung
US5288720A (en) * 1993-04-23 1994-02-22 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
NZ511762A (en) * 1993-07-19 2003-09-26 Univ British Columbia Anti-angiogenic compositions and methods of use
JPH0789849A (ja) 1993-09-20 1995-04-04 Fujisawa Pharmaceut Co Ltd 徐放性製剤
ATE268591T1 (de) * 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
AU726694B2 (en) 1996-03-29 2000-11-16 Smithkline Beecham Corporation Eprosartan dihydrate and a process for its production and formulation
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US5958884A (en) * 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
US6306826B1 (en) * 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
ZA991706B (en) * 1998-03-04 2000-10-03 Takeda Chemical Industries Ltd Sustained-release preparation for Aii Antagonist, production and use thereof.

Also Published As

Publication number Publication date
CN1291888A (zh) 2001-04-18
IL137979A0 (en) 2001-10-31
WO1999044590A1 (en) 1999-09-10
HUP0101439A3 (en) 2002-09-30
EE200000499A (et) 2002-02-15
EP1058541A1 (en) 2000-12-13
NO20004350D0 (no) 2000-09-01
ES2214013T3 (es) 2004-09-01
KR20010086245A (ko) 2001-09-10
LT4800B (lt) 2001-06-25
CA2318446A1 (en) 1999-09-10
NO20004350L (no) 2000-10-03
US20030198676A1 (en) 2003-10-23
US7294344B2 (en) 2007-11-13
DE69914460D1 (de) 2004-03-04
LV12585A (en) 2000-12-20
CA2318446C (en) 2008-09-23
AU2745199A (en) 1999-09-20
BR9908474A (pt) 2000-12-05
DE69914460T2 (de) 2004-10-28
ATE258430T1 (de) 2004-02-15
EP1058541B1 (en) 2004-01-28
PL342684A1 (en) 2001-07-02
US6589547B1 (en) 2003-07-08
HUP0101439A2 (hu) 2001-10-28
SK11902000A3 (sk) 2001-02-12
LT2000082A (en) 2001-03-26
LV12585B (en) 2001-03-20
ZA991706B (en) 2000-10-03

Similar Documents

Publication Publication Date Title
ID25640A (id) Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya
EA200100678A1 (ru) N-уреидоалкил-пиперидины в качестве модуляторов активности рецепторов хемокинов
ID24423A (id) Sediaan farmasi yang terdiri dari klodronat sebagai bahan aktif dan selulosa mikrokristalin tersilisifikasi sebagai eksipien
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
EA200101155A1 (ru) Противоопухолевые соединения, активируемые протеином активации фибробластов (fap)
BR0108471A (pt) Objeto pré-formado para liberar um agente ativo a um paciente, e, processos de formação de um objeto pré-formado para liberar um agente e de liberação de um agente ativo a um paciente
DE60140222D1 (de) "2-Oxo-1-Pyrrolidinderivate und ihre pharmazeutische Verwendung"
DE69841307D1 (de) Verwendung von peroxiden zur bekämpfung der haarigen warzenerkrankung
ATE170508T1 (de) Bisulfit-additionsverbindungen von argininaldehyden und ihre verwendung als thrombininhibitoren und antikoagulantien
DK0976722T3 (da) Benzamidin-derivater
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
DK0689841T3 (da) Pulverpræparat til heling af beskadiget hud
BG66115B1 (bg) Използване на рамиприл или негова фармацевтично приемлива сол за предотвратяване на конгестивна сърдечна недостатъчност
ATE435648T1 (de) Derivaten von nodulisporen säure
BR0214299A (pt) Peptìdeo, inibidor de enzima de conversão de angiotensina, e, agente hipotensivo
BR9910539A (pt) Derivados de 2 - (2 - clorofenil) - 3,4 - dihidro - 2h - pirrol
CA2242224A1 (fr) Microgranules a liberation prolongee contenant du diltiazem comme principe actif
EA200100089A1 (ru) Предотвращение рецидива мигрени
HRP20080521T3 (en) Orodispersible pharmaceutical composition of an antithrombotic compound
ES2185201T3 (es) Formulaciones en forma de gel mejoradas que contienen insecticida.
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
BR9812982A (pt) Agente anti-reumático
DE60034545D1 (de) Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
ATE465718T1 (de) Feste pharmazeutische zubereitung enthaltend levothyroxin- und/oder liothyroninsalze
TH52872A3 (th) สารสำเร็จรูปชนิดที่รักษาการปลดปล่อยได้สำหรับตัวต้านฤทธิ์ aii